FDA Brief

Warning letters Food

FDA warning letter to

Immune & Genetics Protocols, LLC

High riskIssued Mar 30, 2021Posted May 4, 2021Office of Human and Animal Food Operations, East Division IV

FDA warned Immune & Genetics Protocols that website claims its Immune Bio Green Cell treats cancer, diabetes and HIV make it an unapproved new drug.

What happened

In March 2021, FDA reviewed the company's website, biogreencell.com, and its Facebook page, both of which take orders for Immune Bio Green Cell. FDA found statements that the product may help cancer, autism, Asperger's, type 2 diabetes, Crohn's disease, lupus, leukemia, HIV/AIDS and other conditions, plus customer testimonials describing tumor markers falling. There was no inspection; the findings come from the website and social media review.

What FDA found

  1. The company's website and Facebook claims that the product treats or prevents diseases, which makes it a drug under the law.

    Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The product is not generally recognized as safe and effective for those uses, so it is a new drug sold without FDA approval.

    Sections 201(p), 301(d) and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]
  3. The product does not carry adequate directions for use, because a layperson cannot safely use it for diseases that need a doctor's care.

    Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Shipping the misbranded drug across state lines violates the Act.

    Section 301(a) of the Act [21 U.S.C. 331(a)]
  5. The site says USDA approved the product and that it is made in an FDA-registered lab; USDA does not approve drugs or supplements and FDA has no record of the facility being registered.

    Section 415 of the Act [21 U.S.C. 350d]; 21 CFR 1.226

What FDA wants

FDA asks the company to write back within 15 working days describing the specific steps taken to fix the violations, how it will prevent them from recurring, and copies of related documents. If the work cannot be finished in that time, the company must explain the delay and say when it will be done.

Who should pay attention

  • dietary supplement brands that make disease-treatment claims on their websites
  • contract manufacturers and labs that produce supplement powders for such brands
  • marketers and social media managers who post health benefit claims for supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk